Columbia Care Selected by the New Jersey Department of Health to Cultivate, Process and Dispense Medical Cannabis Products
One of six companies awarded fully integrated license out of 146 applicants
New Jersey will be the 14th state where Columbia Care is licensed to operate
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Columbia Care LLC (“Columbia Care”), one of the nation’s leading medical cannabis companies, today announced that, after a rigorous vetting and selection process, it is one of six applicants chosen by the New Jersey Department of Health to apply for a permit to cultivate, process and dispense cannabinoid-based products to qualifying patients. The vertically integrated Columbia Care New Jersey Alternative Treatment Center (ATC) will be based in Vineland and, upon completion of final regulatory steps, will serve patients throughout the state.
“We are proud and grateful to be one of only six new ATCs chosen through the New Jersey Department of Health’s rigorous selection process to cultivate, manufacture and dispense medical cannabis products in New Jersey,” said Nicholas Vita, chief executive officer of Columbia Care. “The priorities of service and caring are the bedrock foundation of our organization. Being given the opportunity to strengthen the health and economic vitality of the Vineland community, while addressing unmet medical needs of patients throughout New Jersey, is part and parcel with the mission and purpose of our organization and reaffirms our position as the dominant national medical cannabis operator in highly selective, highly regulated jurisdictions. We look forward to providing validated and patented pharmaceutical-quality medicines to qualifying patients throughout the Garden State as we launch our vertically integrated operations in 2019. Consistent with our efforts globally, in particular, the 13 other states and territories where we operate in the United States, our cultivation and manufacturing facility will be state-of-the-art, and our dispensary and products will uphold the tradition of all Columbia Care locations by ensuring the highest levels of patient experience and satisfaction while offering the best selection of nationally-branded and patented products.”
The Company’s focus on data-driven innovation and commitment to deliver the highest-quality and most consistent cannabinoid-based medicines to patients with unmet medical needs is made possible by Columbia Care’s vertically integrated cultivation, processing and dispensing ATC that will be designed and operated to best serve patients and stakeholders throughout New Jersey. The facility will be staffed by a dedicated team trained to provide the highest level of professionalism, compassion, confidentiality and respect. For more information about Columbia Care New Jersey, please visit https://col-carenj.com/.
For more information on the New Jersey Medicinal Marijuana Program, please visit: https://www.nj.gov/health/medicalmarijuana/.
About Columbia Care LLC
Columbia Care is one of the nation’s largest and most experienced manufacturer and provider of medical cannabis products and services. Columbia Care has completed more than 750,000 successful patient interactions since its inception and is working in collaboration with some of the most renowned and innovative teaching hospitals and medical centers in the world. Columbia Care is a patient-centered healthcare company setting the standard for compassion, professionalism, quality, caring and innovation for a rapidly expanding new industry focused on providing the transparency and education patients need with the product quality clinicians and consumers expect. By the end of first quarter 2019, Columbia Care anticipates selling its proprietary, pharmaceutical-quality EleCeed™, TheraCeed™ and ClaraCeed™ medications in tablet, vaporization, tincture, suppository and topical formulations throughout its national distribution network in order to treat patients with varying unmet medical needs. For more information on Columbia Care, please visit www.col-care.com.
Josephine Belluardo, Ph.D.
LifeSci Public Relations
Released December 18, 2018